Literature DB >> 8498735

IgG deficiency in adults with recurrent respiratory infections.

V Popa1, K Kim, D C Heiner.   

Abstract

Total IgA, IgM, IgG, and IgG subclasses were measured in 136 consecutive adults with recurrent respiratory infections. Sinus and chest radiographs were also obtained. IgG antibodies to H. influenzae and tetanus toxoid were determined in 27 immunodeficient subjects. Fifty-eight of the 136 were deficient in some immunoglobulin isotype, three in IgA, three in IgM, and 52 in total IgG or one or more IgG subclasses. The most common IgG deficiencies were single IgG subclass deficiencies, particularly IgG3 or IgG4, and a mild decrease in total IgG (between 450 and 650 mg/dL). In 21/27 subjects with IgG deficiency, the response to booster immunization was blunted, even when IgG1 and IgG2 were normal. Thirty-eight patients were smokers, 37 being > 40 years of age at the onset of respiratory infections. Twenty patients were nonsmokers, 19 being < 40 years of age at the onset. In conclusion, adults with recurrent respiratory infections frequently have some variant of IgG deficiency, often associated with a functional impairment of specific antibody response. Smoking may represent a risk factor for IgG deficiency in adults.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8498735

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  10 in total

1.  IgG subclasses in smokers with chronic bronchitis and recurrent exacerbations.

Authors:  I Qvarfordt; G C Riise; B A Andersson; S Larsson
Journal:  Thorax       Date:  2001-06       Impact factor: 9.139

Review 2.  Recent trends in the diagnosis and treatment of sinusitis.

Authors:  M Jorissen
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

3.  A hampered chemoattractant-induced cytoskeletal rearrangement in granulocytes of patients with unexplained severe chronic and relapsing infections of the upper and lower airways. In vitro restoration by G-CSF exposure.

Authors:  P M J Kalkman; W J Fokkens; H J de Wit; J P van de Merwe; H Hooijkaas; J M W van Haarst; H C Hoogsteden; H A Drexhage
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

4.  Clinical and immunological evaluation of patients with mild IgG1 deficiency.

Authors:  D A Van Kessel; P E Horikx; A J Van Houte; C S De Graaff; H Van Velzen-Blad; G T Rijkers
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

5.  IgG subclasses in the serum and sputum from patients with bronchiectasis.

Authors:  S L Hill; J L Mitchell; D Burnett; R A Stockley
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

6.  Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy.

Authors:  F Abrahamian; S Agrawal; S Gupta
Journal:  Clin Exp Immunol       Date:  2009-12-14       Impact factor: 4.330

7.  The spectrum of disease manifestations in patients with common variable immunodeficiency disorders and partial antibody deficiency in a university hospital.

Authors:  L J Maarschalk-Ellerbroek; A I M Hoepelman; J M van Montfrans; P M Ellerbroek
Journal:  J Clin Immunol       Date:  2012-04-13       Impact factor: 8.317

8.  Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD.

Authors:  Fernando Sergio Leitao Filho; Seung Won Ra; Andre Mattman; Robert S Schellenberg; Gerard J Criner; Prescott G Woodruff; Stephen C Lazarus; Richard Albert; John E Connett; Meilan K Han; Fernando J Martinez; Janice M Leung; S F Paul Man; Shawn D Aaron; Robert M Reed; Don D Sin
Journal:  Respir Res       Date:  2018-02-14

Review 9.  Predicting and preventing hospital readmission for exacerbations of COPD.

Authors:  Chia Wei Kong; Tom M A Wilkinson
Journal:  ERJ Open Res       Date:  2020-05-11

10.  Lymphopenia and IgG2 subclass deficiency in patients with severe COVID-19 pneumonia.

Authors:  E M Taban; G R Tintinger; D Joseph; P Gaylard; G Richards
Journal:  Afr J Thorac Crit Care Med       Date:  2021-03-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.